SCHEMBL2921144

SCHEMBL2921144

O=C(Nc1ccc2nc(CN3CCCC3)ccc2c1)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.83

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 11/20 0.83
HTR2C P28335 7/20 0.83
TRPV1 Q8NER1 5/20 0.54
MAPK1 P28482 1/20 0.52
FAAH O00519 1/20 0.52
PLAU P00749 1/20 0.51
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2917966 0.99 MCHR1 (0.81) MCHR1HTR2CTRPV1MAPK1
SCHEMBL2926863 0.91 MCHR1 (0.69) MCHR1HTR2CMAPK1FAAHPLAU
SCHEMBL2925651 0.91 MCHR1 (0.81) MCHR1HTR2CFAAH
SCHEMBL2927983 0.91 MCHR1 (0.81) MCHR1HTR2CNPC1RAB9A
SCHEMBL2927594 0.91 MCHR1 (1.00) MCHR1HTR2CFAAH
SCHEMBL2925591 0.90 MCHR1 (0.80) MCHR1HTR2CMAPK1NPC1RAB9A
SCHEMBL2925096 0.90 MCHR1 (0.80) MCHR1HTR2CFAAH
SCHEMBL2926869 0.90 MCHR1 (0.98) MCHR1HTR2CFAAH
SCHEMBL2952393 0.88 MCHR1 (0.77) MCHR1HTR2CPLAUNPC1RAB9A
SCHEMBL2926771 0.88 MCHR1 (0.76) MCHR1HTR2CTRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1285651-B1 MELANIN CONCENTRATING HORMONE ANTAGONISTS TAKEDA PHARMACEUTICAL (JP) 2010-09-01 EP claimed
US-6930185-B2 Melanin-concentrating hormone antagonist TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-08-16 US claimed
US-20040077628-A1 Melanin-concentrating hormone antagonist TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-22 US claimed
EP-1285651-A1 MELANIN CONCENTRATING HORMONE ANTAGONISTS Takeda Chemical Industries, Ltd. (JP) 2003-02-26 EP claimed
EP-1285651-B1 MELANIN CONCENTRATING HORMONE ANTAGONISTS TAKEDA PHARMACEUTICAL (JP) 2010-09-01 EP disclosed
EP-1285651-B1 MELANIN CONCENTRATING HORMONE ANTAGONISTS TAKEDA PHARMACEUTICAL (JP) 2010-09-01 EP disclosed
US-6930185-B2 Melanin-concentrating hormone antagonist TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-08-16 US disclosed
US-20040077628-A1 Melanin-concentrating hormone antagonist TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-22 US disclosed
EP-1285651-A1 MELANIN CONCENTRATING HORMONE ANTAGONISTS Takeda Chemical Industries, Ltd. (JP) 2003-02-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077628-A1 Melanin-concentrating hormone antagonist MCHR1, MC1R, MCHR2 MCHR1 1/4885HTR2C 107/4885TRPV1 1242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.